<DOC>
	<DOCNO>NCT01966042</DOCNO>
	<brief_summary>Therapeutic neovascularization innovative strategy cardiac tissue recovery due chronic , intense ischemia . Thus stem cell therapy become promising procedure large number patient refractory angina due coronary disease , despite use multiple anti-angina medication , remain severely symptomatic disable angina . Stem cell therapy use autologous cell patient 's bone marrow , show safe associate improved myocardial perfusion , reduce symptom advance coronary artery disease increase functional capacity patient whose therapeutic armamentarium available today exhaust . The study hypothesis infusion autologous mononuclear cell derive patient 's bone marrow deliver via intramyocardial injection patient refractory angina normal slightly depress ventricular function , promote improvement anginal symptom myocardial perfusion induce neoangiogenesis .</brief_summary>
	<brief_title>Study Protocol Intramyocardial Injection Autologous Bone Marrow Stem Cells Refractory Angina</brief_title>
	<detailed_description>This phase II , non-controlled ( single arm ) open label clinical trial . The study approve Institutional Review Board ( IRB ) patient give inform consent prior participation . Refractory angina patient define functional class IV ( angina rest ) accord Canadian Cardiovascular Society Angina Classification ( CCSAC ) despite maximum medical therapy , suitable conventional myocardial revascularization viable myocardium confirm nuclear imaging . Patients evaluate accord different parameter , total period 12 month , primary objective : 1 . Improvement functional class angina symptom ( CCSAC ) patient refractory angina pectoris infusion autologous bone marrow mononuclear cell intervention ; 2 . Improvement myocardial perfusion cell delivery ; 3 . Evaluate safety delivery autologous bone marrow mononuclear cell route individual refractory angina . In screen evaluation , individual presumptive diagnosis class IV refractory angina meet study criterion approach possibility participate study principal investigator . Then , patient submit baseline evaluation serious blood image test . The intervention Bone Marrow Aspiration - For patient , total 100 cc bone marrow aspirate iliac crest time anesthesia cardiac surgery - Infusion - After process cell , surgeon deliver series epicardial injection leave ventricular myocardium . The process bone marrow autologous cell aim enrich content bone marrow aspirate , separate mononuclear fraction cell already differentiate . The postoperative stage conduct identical way patient undergo myocardial revascularization surgery . It important mention ICU ward time vary accord patient 's individual evolution . Finally , first follow visit take place 1 month surgery . The subsequent visit hold 3 , 6 12 month procedure .</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<criteria>Aged 21 year old ; Documented coronary artery disease angiography confirm ischemia myocardial perfusion scintigraphy physical pharmacological stress ; Class IV angina pectoris ( CCSAC ) unresponsive optimize dose least two antianginal medication include nitrate , beta blocker , calcium channel blocker Ranolazine ) well aspirin antiplatelet agent plus statin therapy ; Considered candidate either percutaneous catheter surgical myocardial revascularization due either anatomical type , extent coronary disease target vessel , caliber distal vessel ; Ejection fraction &gt; 45 % Transthoracic echocardiogram Doppler Simpson method ; Myocardial perfusion scintigraphy show area myocardial ischemia supply viable tissue . Significant Valvular Heart Disease ; Chronic kidney disease require renal replacement therapy ; Severe comorbidities associate reduction life expectancy le 5 year ; Ongoing abusive use alcohol illegal drug ( Based Diagnostic Statistical Manual ( DSM ) IV CAGE questionnaire ) ; Positive Serologic test HIV , Human Tcell lymphotrophic virus ( HTLV ) , Hepatitis A , B C ; History Malignant neoplasia last 2 year ; Participation study cell therapy last year ; Pregnancy Breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Refractory angina</keyword>
	<keyword>Cell Therapy</keyword>
	<keyword>Bone Marrow</keyword>
	<keyword>Mononuclear Cells</keyword>
</DOC>